Zydus Lifesciences wins FDA final approval for Isoproterenol HCL injection
Zydus Lifesciences has secured final approval for Isoproterenol Hydrochloride (HCL) Injection USP, 0.2 mg/mL and 1 mg/5 mL (0.2 mg/mL) single-dose vials from the US Food and Drug Administration (FDA). The approved product is a generic version of Isuprel Injection. Isoproterenol hydrochloride injection has been approved for improving hemodynamic status in patients in distributive shock […]
